PaxVax CEO Ken Kelley will present at the 13th annual BIO Investor Forum, which will be held on Oct. 7-8 in San Francisco, Calif.
The forum is hosted by the Biotechnology Industry Organization (BIO). Executives from private and emerging public companies are expected to present.
“PaxVax is at an important inflection point catalyzed by our acquisition of Vivotif, a globally marketed vaccine for typhoid, and the anticipated BLA approval and launch next year of our second commercial product, a single-dose oral cholera vaccine candidate,” Kelley said.
The company is focusing on acquiring and developing vaccines for travelers that are safe, effective, affordable and easy to use. PaxVax's research and production pipelines include a vaccine candidate for cholera. The U.S. Centers for Disease Control recognizes cholera as a category B bioterrorism agent, the second-highest priority level of agents for the agency.PaxVax is a Redwood City, Calif-based company that was founded in 2007. It seeks to profit by developing vaccines while also benefiting society by making vaccines available globally.